IPO Ideas

Go to page

Browse IPO Ideas — market data, blogs, legal pages, and more.

Avience Biomedicals IPO logo

Avience Biomedicals IPO

BBSMENSEListed
Listed at
395.2
+90.00%

Avience Biomedicals IPO is a SME book building IPO. Issue size is 30 Cr. Price band is ₹196 to ₹208 per share. Minimum investment is ₹2.50 L. Lot size is 600 shares. Open from 18 Jun 2026 to 22 Jun 2026. Allotment on 23 Jun 2026. Listing on 25 Jun 2026 at NSE. Managed by Fintellectual Corporate Advisors Pvt.Ltd. Registrar: Skyline Financial Services Private Ltd. Key details for GMP, subscription, price, allotment, and listing in one place.

Avience Biomedicals IPO overview

Avience Biomedicals IPO Key figures

Price band, lot, minimum application, and issue window at a glance.

Price band
₹196 to ₹208
Lot size
600 shares / lot
Min investment
₹2,49,600

Avience Biomedicals IPO progress

Subscription, allotment, refund, share credit, and listing milestones.

Listed

Avience Biomedicals IPO lot size

CategoryLotsSharesAmount
Retail (Min)21,2002,49,600
S-HNI (Min)31,8003,74,400
S-HNI (UPI)42,4004,99,200
S-HNI (Max)84,8009,98,400
B-HNI (Min)95,40011,23,200

Quick Profit Calculator for Avience Biomedicals IPO

Pre-filled: Issue Price = ₹208, Lot Size = 600 shares, Listing Price = ₹395.2

CategoryLotsInvestmentAt listingProfit
Retail (Min)22,49,600395+₹2,24,640
S-HNI (Min)33,74,400395+₹3,36,960
S-HNI (UPI)44,99,200395+₹4,49,280
S-HNI (Max)89,98,400395+₹8,98,560
B-HNI (Min)911,23,200395+₹10,10,880

Profit based on the official listing price for each investor category.

About Avience Biomedicals IPO

From the company / RHP narrative.

Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry. Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets. The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas. In addition to manufacturing, the Company also act as distributors and traders of medical equipment. The company's manufacturing unit is situated in Noida, Uttar Pradesh. The company offers a comprehensive range of diagnostic solutions, including: Rapid Test Kits: Products like AVISURE Dengue Combo Test, Malaria Rapid Test (Pf/Pv), and AVISURE Syphilis Rapid Test. Biochemistry Analyzers and Reagents: Devices like the BS-240 Fully Auto Analyzer and reagents like AVIENBIO Albumin Kit. Molecular Diagnostics: COVID-19 detection kits, including the COVID-19 Hid RTqPCR ASSAY. Hematology Analyzers: Models like the BC-20s 3-Part Hematology Analyzer. Medical Devices: Oxygen concentrators (Oxy-5 and Oxy-10) and viral transport solutions (VTM). As of January 31, 2026, the company had 75 permanent employees and 33 contractual employees Competitive Strength Strong Industry Experience and Expertise. Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits. Strong distribution network across India and is growing its international footprint. Cost-Effective and Affordable Solutions. Stringent quality control processes and complies with ISO standards and regulatory approvals.

Avience Biomedicals IPO Issue Objective

How the issuer plans to use IPO proceeds.

Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh Funding the working capital requirements of the Company General Corporate Purposes Total

Avience Biomedicals IPO FAQs

A quick overview of key terms, dates, and how to track this IPO.

What is Avience Biomedicals IPO?
Avience Biomedicals IPO is a public issue where the company offers its shares to investors through the stock exchange, allowing retail, HNI, and institutional participation.
What is the IPO price band of Avience Biomedicals IPO?
The IPO price band of Avience Biomedicals IPO is ₹₹196 to ₹208 per share, as mentioned in the issue details.
What is the minimum investment required for Avience Biomedicals IPO?
The minimum investment in Avience Biomedicals IPO is ₹2,49,600, based on the applicable lot size for retail investors.
What is the lot size of Avience Biomedicals IPO?
The lot size of Avience Biomedicals IPO is 600 shares per lot, and applications must be made in multiples of this lot size.
What are the opening and closing dates of Avience Biomedicals IPO?
Avience Biomedicals IPO opens on 18 Jun 2026 and closes on 22 Jun 2026, as per the announced schedule.
What is Avience Biomedicals IPO subscription status?
Avience Biomedicals IPO subscription status shows the level of demand across retail, HNI, and institutional investor categories during the issue period.
What is Avience Biomedicals IPO GMP today?
Avience Biomedicals IPO GMP (Grey Market Premium) today is around ₹110, reflecting current grey market activity before listing.
Is Avience Biomedicals IPO GMP positive or negative?
Avience Biomedicals IPO GMP is currently subject to change, based on prevailing grey market trends. GMP may change over time.
What does Avience Biomedicals IPO GMP indicate for listing?
A positive Avience Biomedicals IPO GMP may indicate market interest ahead of listing, while actual listing performance depends on subscription response and market conditions.
When is Avience Biomedicals IPO listing date?
The expected listing date of Avience Biomedicals IPO is 25 Jun 2026, subject to completion of the allotment process.
Where can I check Avience Biomedicals IPO allotment status?
Avience Biomedicals IPO allotment status can be checked online once the allotment process is completed using application or PAN details.
Can Avience Biomedicals IPO subscription and GMP change before listing?
Yes, Avience Biomedicals IPO subscription figures and GMP may change during the issue period and before listing based on market activity.

Avience Biomedicals IPO Ratings & reviews

Community ratings and reviews — not financial advice.

No ratings yet — be the first to share your experience.

Loading ratings…
Follow the latest IPO & unlisted research on iOS and Android.